HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision

This article was originally published in The Tan Sheet

Executive Summary

Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.

You may also be interested in...

If P&G Seeks OTC Sale, Pharma Buyers Might Line Up

P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely have plenty of potential buyers.

CEOs In Transition: Internal The Norm, But External Delivers Strong Returns

CEO changes are underway across big pharma and biotech, marking a time of substantial leadership transition for the industry. New CEOs are usually insiders, but external hires appear to be more willing to implement change to improve shareholder returns, according to an analysis from Leerink.

Glaxo's Witty Lists 'Fundamentals' For Consumer Business Prowess

Andrew Witty tells analysts Glaxo is strong in areas critical to success in the consumer health products space: margin, scale and potential OTC switches. The Flonase Allergy Relief OTC switch shows "nobody is switching products better than GSK," he says.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts